Business Wire

DEWIZ

10.8.2021 11:51:08 CEST | Business Wire | Press release

Share
deWiz Names Laszlo Varga as Chief Executive Officer

deWiz’s Board of Directors, including co-founders Christian Bergh and Markus Westerberg, have announced Laszlo Varga as deWiz’s new Chief Executive Officer, starting August 16. Varga will apply his extensive experience leading e-commerce businesses like Gents and EuroFlorist to deWiz’s go-to-market strategy in golf and help develop strategic extensions for deWiz’s technology with other sports and disciplines. As CEO, Varga will oversee the start-up’s transition to a comprehensive global strategy by aligning all aspects of deWiz businesses using his expertise across consumer products, digital marketing, and direct sales.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210810005498/en/

Debuting this summer, deWiz’s revolutionary wearable technology delivers groundbreaking instantaneous feedback and high-precision swing data that accelerates golfers’ pace of learning and adds consistency. deWiz’s introduction to the golf and business world has already created a “buzz” with it being described by Forbes as looking to bring a “jolt to the golf training aid market ;” being profiled in Sweden’s leading financial media, Dagens Industri ; and being featured in Sport Techie’s Startups series .

“On behalf of my co-founder Markus and the deWiz board, I am thrilled to have Laszlo join our journey as we strive to help golfers improve faster with our science-backed technology as their competitive edge. As I continue as Chief Operations Officer for deWiz and as a board member, it’s a testament to how much we’ve accomplished since founding the company to have attracted somebody of Laszlo’s caliber and business acumen to lead our global strategy moving forward,” said Christian Bergh, co-founder and COO of deWiz.

“I’m super excited and proud to join the deWiz team. The product is truly revolutionary in helping athletes improve their performance by combining neural science with instant feedback and unmatched data capture. There is nothing else like deWiz in the golf market and the feedback we've gotten from the early users is overwhelmingly positive. With my experience and understanding of global e-commerce and direct sales to consumers, I hope to contribute to the accelerated growth and success of this awesome company that is on the front edge of innovation," said Laszlo Varga, CEO of deWiz.

Varga has a strong background in multi-national e-commerce and direct-to-consumer sales. Prior to joining deWiz, Laszlo was the CEO of Gents, a brand and online retailer for male grooming products. Before joining Gents, Varga was the CEO of Euroflorist, Europe’s largest flowers by wire company where he had a long and successful career, serving previously as Chief Operations Officer and Online Director, heading the online transition of sales. Varga’s entrepreneurial spirit and busines building skillset is also relied upon as a board member for Gents, CoolStuff and BoneProx. Varga is based in Malmö, Sweden, where he has spent the majority of his professional career after graduating from San Diego State University and competing at an elite level in kayaking.

DEVELOPED BY EXPERTS, TESTED BY PROS: deWiz’s has been in development for more than five years and has attracted an impressive roster of ambassadors, including 2020 U.S. Open Champion Bryson DeChambeau, 10-time Major Champion Annika Sorenstam, 3-time Major Champion Vijay Singh, 2-time Major Champion Lydia Ko, 2016 Open Champion Henrik Stenson, 2019 Houston Open Champion Lanto Griffin and 2-time World Long Drive Champion Tim Burke. deWiz’s user-friendly app and wearable tech tracks the precise position of a golfer’s hands throughout their swing, providing a 3D analysis and delivering data showcasing Transition , Length of Backswing , Wedge Distance and Tempo . These unique deWiz data points provide measurable metrics that any avid golfer, teaching professional or world-class player can utilize to efficiently refine their swing. Currently for sale for 699 USD, deWiz is available across the United States, Canada, Europe, and South Korea (more markets opening regularly – visit the website for the latest updates). Please visit dewizgolf.com for more details on how to improve your swing faster or download the app to demo its features via Apple’s App Store or Google Play.

ABOUT deWiz
The deWiz golf training platform has been developed by former European Tour pro, PGA of Sweden certified instructor and motor learning author, Markus Westerberg, and entrepreneur and technology business leader Christian Bergh. As a Swedish developed and produced product, deWiz is focused on its mission to help golfers around the world elevate their enjoyment of the game through innovative technology that accelerates the pace of learning. deWiz’s revolutionary wearable technology delivers groundbreaking instantaneous feedback that is based on a scientific approach of breaking cycles within motor learning and propelling golfers to improve faster.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye